Faster Approval Does Not Mean Faster Reimbursement
Several Factors Can Prolong HTA Decision Time
Securing accelerated assessment for a drug in any regulatory jurisdiction is a major boost for drug companies, but it does not necessarily translate into an earlier reimbursement decision.
You may also be interested in...
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.